ライフサイエンスコーパス: alpha-fetoprotein

1 P=.01 for alkaline phosphatase, P<.0001 for alpha-fetoprotein).

2 (KO) tumors that express increased levels of alpha-fetoprotein.

3 ted by MELD score, HCC size, HCC number, and alpha-fetoprotein.

4 lar invasion, metastasis, serum albumin, and alpha-fetoprotein.

5 ed expression of fetal liver genes including alpha-fetoprotein.

6 d concomitantly with increased expression of alpha-fetoprotein.

7 yonic antigen, cytokeratin (CK) 7, CK20, and alpha-fetoprotein.

8 hepatocytes expressing the oncofetal marker, alpha-fetoprotein.

9 arly hepatic neoplasia and increase in serum alpha-fetoprotein.

10 respective of tumor burden or serum level of alpha-fetoprotein.

11 per cm increase [1.04-1.11]; p<0.0001), log alpha-fetoprotein (1.10 per unit increase [1.02-1.20]; p

12 Of patients with an elevated pretreatment alpha-fetoprotein, 85% were found to have declining alph

13 to the homogeneous liquid-phase detection of alpha-fetoprotein, a common tumor marker, the system sho

14 calization of beta-catenin and expression of alpha-fetoprotein, a prognostic marker of hepatocellular

15 alpha-fetoprotein (MSAFP) or amniotic fluid alpha-fetoprotein (AFAFP) levels or abnormalities visual

16 an 3 years, 3-7 years, and 8 years or older; alpha fetoprotein (AFP) concentration of 100 ng/mL or lo

17 aximal tumor diameter of 3 to 5 cm and serum alpha fetoprotein (AFP) greater than 100 ng/mL at transp

18 Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm,

19 A technique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups.

20 s carcinoembryonic antigen (CEA), bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) we

21 immunodominant and subdominant epitopes from alpha fetoprotein (AFP), restricted by HLA-A*0201, which

22 alpha fetoprotein (AFP)-derived peptide epitopes can be

23 Elevated alpha-fetoprotein (AFP) >/= 10,000 ng/mL was associated

24 varian GCTs were resected and monitored with alpha-fetoprotein (AFP) ("watch-and-wait" approach).

25 ubanalysis for patients with a high level of alpha-fetoprotein (AFP) (>100 ng/dL) was conducted.

26 ic marker A6 (94.57% +/- 0.033%), as well as alpha-fetoprotein (AFP) (75.92% +/- 0.071%).

27 motherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonad

28 FLEC were identified: cells expressing both alpha-fetoprotein (AFP) and albumin, but not CK-19; cell

29 Mean preoperative serum alpha-fetoprotein (AFP) and beta-human chorionic gonadot

30 We used two model biomarkers [alpha-fetoprotein (AFP) and cancer antigen 125 (CA125)]

31 of this study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombi

32 ts who had twice yearly screening with serum alpha-fetoprotein (AFP) and hepatic ultrasound than in p

33 he rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic gonadotrophi

34 her levels of alkaline phosphatase (ALP) and alpha-fetoprotein (AFP) and lower level of alanine amino

35 HCC surveillance with alpha-fetoprotein (AFP) and ultrasonography has been rec

36 We identified alpha-fetoprotein (AFP) and ultrasound tests performed f

37 on levels of mRNA and/or protein for WT1 and alpha-fetoprotein (AFP) are increased.

38 Serum levels of alpha-fetoprotein (AFP) are influenced not only by the p

39 In addition, we have identified the alpha-fetoprotein (AFP) as a novel downstream target of

40 Twenty-three patients had elevated alpha-fetoprotein (AFP) at diagnosis.

41 ter Transplant (RETREAT), which incorporates alpha-fetoprotein (AFP) at liver transplantation (LT), m

42 accurate quantitation of biomarkers such as alpha-fetoprotein (AFP) can be a key aspect of early sta

43 her the HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an

44 7 HBsAg-positive Alaska native carriers with alpha-fetoprotein (AFP) determinations every 6 months.

45 We previously showed that mouse alpha-fetoprotein (AFP) enhancer 3 activity is highly re

46 pression under the control of an albumin and alpha-fetoprotein (AFP) enhancer and promoter (AFP-Notch

47 Although alpha-fetoprotein (Afp) falls into this class of genes,

48 xamine the oval cell response and associated alpha-fetoprotein (AFP) gene expression by combining 2-A

49 ve shown that p53 represses hepatic-specific alpha-fetoprotein (AFP) gene expression by direct intera

50 alpha-fetoprotein (AFP) gene expression occurs in the yo

51 Aberrant expression of the alpha-fetoprotein (AFP) gene is a diagnostic tumor marke

52 The alpha-fetoprotein (AFP) gene is an important model of de

53 Aberrant expression of the alpha-fetoprotein (AFP) gene is characteristic of a majo

54 The alpha-fetoprotein (AFP) gene is expressed abundantly in

55 The alpha-fetoprotein (AFP) gene is transcribed at high leve

56 nked coupling element (PCE), a site from the alpha-fetoprotein (AFP) gene promoter.

57 nd core promoter of the hepatic tumor marker alpha-fetoprotein (AFP) gene.

58 analyzed methylation of the rat albumin and alpha-fetoprotein (AFP) genes by hydridizing labeled cDN

59 For decades, alpha-fetoprotein (AFP) has been used as a differentiati

60 ng the neutrophil-lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) have been associated with recurr

61 CK19 co-expressed with HepPar1, c-kit, and alpha-fetoprotein (AFP) in parenchymal cells in massive

62 formance status, Child-Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual surviva

63 orted to be more sensitive and specific than Alpha-fetoprotein (AFP) in the diagnosis of HCC among th

64 alpha-Fetoprotein (AFP) independently predicted tumor re

65 Alpha-fetoprotein (AFP) is a biomarker for hepatocellula

66 Serum alpha-fetoprotein (AFP) is a biomarker for hepatocellula

67 alpha-Fetoprotein (AFP) is a potential target for immuno

68 The L3 isoform of alpha-fetoprotein (AFP) is a specific marker for hepatoc

69 alpha-Fetoprotein (AFP) is an oncofetal Ag and has intri

70 alpha-fetoprotein (AFP) is an oncofetal Ag that is highl

71 Alpha-fetoprotein (AFP) is considered to be an indicator

72 for sensitive detection of cancer biomarker alpha-fetoprotein (AFP) is described that uses a graphen

73 alpha-Fetoprotein (AFP) is frequently used as a diagnost

74 ent and expression of the hepatoblast marker alpha-fetoprotein (Afp) is lost.

75 Alpha-fetoprotein (AFP) is often derepressed in human he

76 Although serum alpha-fetoprotein (AFP) is often used to detect hepatoce

77 noma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose.

78 Alpha-fetoprotein (AFP) is widely used as a surveillance

79 An alpha-fetoprotein (AFP) level > 1,000 ng/mL, total tumor

80 ent cohort of 721 patients (542 men), median alpha-fetoprotein (AFP) level at the time of LT was 8.3

81 (BCLC) staging system, tumor size, and serum alpha-fetoprotein (AFP) level were investigated using Co

82 cic lymph node metastases and a rising serum alpha-fetoprotein (AFP) level.

83 High maternal serum alpha-fetoprotein (AFP) levels during pregnancy may be i

84 Nonetheless, serial measurement of alpha-fetoprotein (AFP) levels in serum and hepatic ultr

85 (ADI) in terms of toxicity, tumor response, alpha-fetoprotein (AFP) levels, and serum arginine level

86 lated with tumor histology and pretransplant alpha-fetoprotein (AFP) levels.

87 yuridine (BrdU) labeling, liver DNA content, alpha-fetoprotein (AFP) mRNA production, and apoptosis a

88 s to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular ca

89 Alpha-fetoprotein (AFP) represents a classical model sys

90 Our group has shown that a rising natural alpha-fetoprotein (AFP) slope (NAS) correlates with tumo

91 alpha-Fetoprotein (AFP) transcription is activated early

92 pressor p53 in the regulation of the hepatic alpha-fetoprotein (AFP) tumor marker gene.

93 osorbent assay was developed to detect human alpha-fetoprotein (AFP) using carbon dots (C-Dots).

94 Serum alpha-fetoprotein (AFP) values in patients with and thos

95 In 17 patients the baseline serum alpha-fetoprotein (AFP) was >or= 1,000 ng/mL; in four of

96 To use the device under optimal conditions, alpha-fetoprotein (AFP) was detected at a limit of detec

97 Remarkably, expression of alpha-fetoprotein (AFP) was highly correlated with the m

98 Levels of human alpha-fetoprotein (AFP) were monitored in the serum of a

99 the hepatitis B surface antigen (HBsAg) and alpha-fetoprotein (AFP) with the lowest concentration of

100 adhesion molecule (EpCAM)(+) HCC cells from alpha-fetoprotein (AFP)(+) tumors with cancer stem/proge

101 ls with activated Wnt signaling occupying an alpha-fetoprotein (AFP)+/cytokeratin-19 (CK-19)-positive

102 As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocel

103 alpha-Fetoprotein (AFP), a tumor marker currently used f

104 reased hepatic associated gene expression of alpha-fetoprotein (AFP), Albumin (Alb), Glucose-6-phosph

105 ltigene cluster that includes albumin (ALB), alpha-fetoprotein (AFP), and alpha-albumin/afamin (AFM).

106 e endodermal markers, including HNF4, GATA4, alpha-fetoprotein (AFP), and HNF3beta.

107 , with some potential advantages compared to alpha-fetoprotein (AFP), but its role in the context of

108 biomarkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), cancer antigen 125 (CA125), and

109 The fetal hepatocytes expressed alpha-fetoprotein (AFP), cytokeratin (CK) 19, albumin, a

110 sed overlapping peptides spanning the entire alpha-fetoprotein (AFP), glypican-3 (GPC-3), melanoma-as

111 The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations.

112 tive for markers of visceral endoderm (DAB2, alpha-fetoprotein (AFP), HNF4).

113 , a factor required for HSC homing, and also alpha-fetoprotein (AFP), indicating that they are fetal

114 ed hepatocellular carcinoma (HCC) biomarkers alpha-fetoprotein (Afp), insulin-like growth factor 2 (I

115 They are negative for alpha-fetoprotein (AFP), intercellular adhesion molecule

116 trongly associated with elevated circulating alpha-fetoprotein (AFP), low rate of necrosis/fibrosis a

117 Serum alpha-fetoprotein (AFP), normally highly expressed in th

118 10 mRNA expression was associated with serum alpha-fetoprotein (AFP), tumor-node-metastasis (TNM) sta

119 With this approach, an aptamer specific to alpha-fetoprotein (AFP), which is a biomarker for liver

120 ted polymer (MIP) for trace level sensing of alpha-fetoprotein (AFP), which is a well know cancer bio

121 sodium (MELD-Na), tumour burden score (TBS), alpha-fetoprotein (AFP), year of transplantation, underl

122 developmental repression of the tumor marker alpha-fetoprotein (AFP).

123 stic implication by determining the level of alpha-fetoprotein (AFP).

124 n (CK) 19, albumin +/-, and are negative for alpha-fetoprotein (AFP).

125 is of HCC in Japanese patients compared with alpha-fetoprotein (AFP).

126 p53 regulation of the HCC tumor marker gene, alpha-fetoprotein (AFP).

127 -specific silencing of the tumor marker gene alpha-fetoprotein (AFP).

128 human hepatocellular carcinomas overexpress alpha-fetoprotein (AFP).

129 ltrasensitive detection of cancer biomarker, alpha-fetoprotein (AFP).

130 osed total tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP; </=400 ng/mL) score.

131 occurrence as well as patients with negative alpha-fetoprotein (AFP; n = 1), resulting in 24 patients

132 2 recently identified HCC subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and EpCAM(-) AFP(-) HCC).

133 tumor-associated self-antigens (for example, alpha-fetoprotein [AFP]).

134 of antibodies specific for epithelial cells (alpha-fetoprotein [AFP], albumin [ALB], pancytokeratin [

135 e Panel recommended measuring three markers (alpha-fetoprotein [AFP], human chorionic gonadotropin [h

136 The vast majority of alpha fetoprotein(+), albumin(+), cytokine-19(+), and E-

137 f five (80%) patients with elevated markers (alpha-fetoprotein alone in three, alpha-fetoprotein and

138 erum alpha-fetoprotein and ferritin or serum alpha-fetoprotein alone, including four with coagulopath

139 albumin gene family is comprised of albumin, alpha-fetoprotein, alpha-albumin (afamin), and the more

140 encode the serum transport proteins albumin, alpha-fetoprotein, alpha-albumin, and vitamin D-binding

141 fibrinogen, fibronectin, transthyretin, and alpha-fetoprotein, an essential feature for functional H

142 l examination, measurement of tumor markers (alpha fetoprotein and human chorionic gonadotropin), and

143 te that this enhancer region is required for alpha-fetoprotein and albumin activation early in liver

144 lls were analyzed by immunocitochemistry for alpha-fetoprotein and albumin expression, qPCR for hepat

145 strate that RNA polymerase II loading on the alpha-fetoprotein and albumin promoters is reduced in th

146 enriched (45-70%) for cells that express the alpha-fetoprotein and albumin proteins.

147 a member of a cluster that includes albumin, alpha-fetoprotein and alpha-albumin genes.

148 f these genes, particularly that of albumin, alpha-fetoprotein and alpha-albumin, and their liver-spe

149 d markers (alpha-fetoprotein alone in three, alpha-fetoprotein and beta human chorionic gonadotropin

150 d higher than normal concentrations of serum alpha-fetoprotein and ferritin or serum alpha-fetoprotei

151 The prognostic information provided by alpha-fetoprotein and human chorionic gonadotrophin in t

152 Serum tumor markers alpha-fetoprotein and human chorionic gonadotrophin were

153 , 134-142 mEq/L [134-142 mmol/L]), and serum alpha-fetoprotein and human chorionic gonadotropin level

154 Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of T

155 iated with induction of the human HCC marker alpha-fetoprotein and the stem cell marker CD133.

156 en second-trimester levels of maternal serum alpha-fetoprotein and the subsequent risk of SIDS.

157 lutamyl transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt expor

158 tients with slow serum tumor marker decline (alpha-fetoprotein and/or human chorionic gonadotrophin)

159 nti-carcinoembryonic antigen, CK7, CK20, and alpha-fetoprotein) and in the distinction from cholangio

160 nd-stage liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were

161 , secreted hepatic proteins such as Albumin, Alpha Fetoprotein, and Fibrinogen, metabolized ammonia,

162 l expression/coexpression of DCAMKL-1, CK19, alpha-fetoprotein, and active c-Src.

163 iated liver phenotype: albumin, transferrin, alpha-fetoprotein, and alpha1-antitrypsin.

164 with the expression of biliary cytokeratins, alpha-fetoprotein, and c-Met by FIHC.

165 tion expressed both donor marker (DPPIV) and alpha-fetoprotein, and some differentiated into hepatocy

166 total bilirubin, albumin, prothrombin time, alpha-fetoprotein, and tumor number, which were incorpor

167 tribution; levels of bilirubin, albumin, and alpha-fetoprotein; and WHO/EASL response rate predicted

168 tients with HBV had larger tumors and higher alpha-fetoprotein but less satellites and macrovascular

169 ibiting cytoplasmic/nuclear beta-catenin and alpha-fetoprotein but not CK19, HNF1beta, or Trop-2.

170 4, cytokeratin 19 (CK19), transthyretin, and alpha-fetoprotein by day 7, and expressed CK18, HNF-4, a

171 M+, c-met+, SSEA-4+, CK18+, CK19+, albumin-, alpha-fetoprotein-, CD44h+, and vimentin+.

172 not significantly different among the three alpha-fetoprotein classes (P = 0.493).

173 ed according to randomising centre and serum alpha-fetoprotein concentration (<400 ng/mL and >/=400 n

174 ction was assessed by expression of albumin, alpha-fetoprotein, cytochrome P4502E1, cytokeratin-18, t

175 Rat ED14 FLSPC are alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprot

176 re alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19(-) and contain all o

177 tumors and embryonal carcinomas positive for alpha-fetoprotein, cytokeratin AE1/AE3, and CD30.

178 d CaM kinase-like-1 (DCAMKL-1), Lgr5, CD133, alpha-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-M

179 heral zones were simultaneously positive for alpha-fetoprotein, cytokeratin-19, and c-kit, indicating

180 lls express the classical oval cell markers (alpha-fetoprotein, cytokeratin-19, OV-1 antigen, a6 inte

181 In conclusion, alpha-fetoprotein-derived peptide appears to be a novel

182 ever, when the values of known serum markers alpha fetoprotein, des-gamma carboxyprothrombin, and GP7

183 A raised maternal serum level of alpha-fetoprotein during the second trimester of pregnan

184 e replaced the endodermal enhancers with the alpha-fetoprotein endodermal enhancers (H19Afp).

185 ressing Cre-recombinase under control of the alpha fetoprotein enhancer and albumin promoter.

186 To directly examine whether the alpha-fetoprotein enhancer region could regulate the alb

187 nder the control of the albumin promoter and alpha-fetoprotein enhancer to ablate Jag1 in hepatoblast

188 he expression of vimentin, beta-III tubulin, alpha-fetoprotein, eomesodermin, HEB, ARNT, and FoxD3 as

189 rial abdominal computed tomography and serum alpha-fetoprotein every 6 months.

190 oval cell proliferation and a lower level of alpha-fetoprotein expression as compared with control an

191 ogs induced albumin expression and decreased alpha-fetoprotein expression in HepG2 cells, which sugge

192 e basis of the similarities between Gpc3 and alpha-fetoprotein expression in the liver, we reasoned t

193 F-1 expression caused a dramatic decrease in alpha-fetoprotein expression, implying impaired oval cel

194 e staining (absent or diffuse), and variable alpha-fetoprotein expression.

195 ok 2, spalt-like transcription factor 4, and alpha-fetoprotein expression; and high coordinated expre

196 The alpha-fetoprotein gene (AFP) is tightly regulated at the

197 The albumin and alpha-fetoprotein genes are adjacent and express closely

198 e expression of endogenous SAA, albumin, and alpha-fetoprotein genes.

199 the downstaging group included pretreatment alpha-fetoprotein >/=1,000 ng/mL (multivariate hazard ra

200 redicting treatment failure was pretreatment alpha-fetoprotein >1,000 ng/mL.

201 U/L) was present in all hepatitis patients, alpha-fetoprotein >10 ng/ml in 2/8 (25%), and cryoglobul

202 alyses identified age <65 years (P = 0.038), alpha-fetoprotein >200 ng/mL (P = 0.04), and vascular in

203 ular invasion, exceeding Milan criteria, and alpha-fetoprotein>200 ng/mL.

204 f embryonic stem (ES) cells expressing human alpha-fetoprotein (hAFP) under control of the endogenous

205 ize of tumors, presence of metastases, serum alpha-Fetoprotein, hepatitis serologies, severity of hep

206 They also expressed alpha-fetoprotein, hepatocyte nuclear factor-4a, and a m

207 ted clinical diagnostic application, such as alpha-fetoprotein in liver carcinoma, and kallikreins 6

208 evaluate the prognostic usefulness of serum alpha-fetoprotein in patients with well-compensated cirr

209 cificity of des-gamma-carboxyprothrombin and alpha-fetoprotein in the diagnosis of hepatocellular car

210 ted on a clinically relevant assay to detect alpha-fetoprotein, in which a 42-fold enhancement to sen

211 The proposed Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score was the bes

212 (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assess

213 Alpha-fetoprotein is a tumor marker that has been used f

214 Alpha-fetoprotein is the most widely used tumor marker,

215 zard ratio, 1.61; 95% CI: 1.3-2.1) and serum alpha-fetoprotein level >/=455 ng/mL (hazard ratio, 2.15

216 Patients with larger (3-5 cm) tumors, serum alpha-fetoprotein level >/=455 ng/mL, or a MELD score >/

217 The size of the lesion, an alpha-fetoprotein level >2000 ng/ml, and vascular invasi

218 a cirrhotic liver in the presence of a serum alpha-fetoprotein level >400 ng/mL also is diagnostic.

219 An alpha-fetoprotein level >500 ng/mL predicted poorer outc

220 s showed significant effects of pretreatment alpha-fetoprotein level (P = .03) and ADC ratio (P < .00

221 rnational normalized ratio greater than 1.1, alpha-fetoprotein level greater than 20 ng/mL, multiple

222 A preablative serum alpha-fetoprotein level higher than 200 ng/mL (hazard ra

223 priate candidates for liver transplantation; alpha-fetoprotein level limitations should be incorporat

224 mal range, 13-60 U/L [0.21-1.0 mukat/L]), an alpha-fetoprotein level of 3.81 ng/ mL (normal range, 0-

225 ory studies were significant for an elevated alpha-fetoprotein level of 7051 ng/ml and mild anemia.

226 vascular invasion, extrahepatic disease, and alpha-fetoprotein level to best supportive care plus ora

227 were slightly depressed at 121,000 muL, and alpha-fetoprotein level was 89 mug/L.

228 was achieved in 10 patients (83.3%), and the alpha-fetoprotein level was also decreased to normal in

229 Serum alpha-fetoprotein level was elevated in 26 patients.

230 erum markers for ovarian cancer were normal (alpha-fetoprotein level, 1.6 microg/L; Ca-125 level, 15

231 clinical factors (age, gender, preoperative alpha-fetoprotein level, hepatitis serology, number of t

232 oenvironment also correlated with high serum alpha-fetoprotein levels (P < 0.001), macrovascular inva

233 -Pugh scores (P = .003), higher pretreatment alpha-fetoprotein levels (P = .04), and a greater number

234 It is unknown whether alpha-fetoprotein levels also predict the risk of SIDS.

235 tion between second-trimester maternal serum alpha-fetoprotein levels and the risk of SIDS, which may

236 Patients were followed with CT scan and alpha-fetoprotein levels every 3 months for 2 years post

237 etoprotein, 85% were found to have declining alpha-fetoprotein levels from a pretreatment mean of 140

238 ence, 2.7 per 10,000 births among women with alpha-fetoprotein levels in the lowest quintile and 7.5

239 and increased aspartate aminotransferase and alpha-fetoprotein levels were associated with HCC (p < 0

240 otransferase/alanine aminotransferase ratio, alpha-fetoprotein levels, and IL28B single-nucleotide po

241 talian Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replac

242 markers of tumor aggressiveness (high serum alpha-fetoprotein levels, P = 0.038; satellite nodules,

243 [LPA(16:0)], where it correlated with plasma alpha-fetoprotein levels.

244 xtent of cellular differentiation, and serum alpha-fetoprotein levels.

245 esence of a relatively stable genome and low alpha-fetoprotein levels.

246 to HACE, as measured by imaging studies and alpha-fetoprotein levels.

247 tumor shrinkage and serial decrease of serum alpha-fetoprotein levels.

248 when inserted into the normally nonimprinted alpha fetoprotein locus.

249 The albumin-alpha-fetoprotein locus epitomizes the main features of

250 in the genome, downstream of H19 and at the alpha-fetoprotein locus on chromosome 5.

251 hosis should be screened with ultrasound and alpha-fetoprotein measurement every 6 months.

252 rveillance for HCC is by ultrasonography and alpha-fetoprotein measurements every 6-12 months.

253 ariables (Model for End-Stage Liver Disease, alpha-fetoprotein, Milan-Criteria status, and radiologic

254 logical response to loco-regional therapies, alpha-fetoprotein modification, inflammatory markers, an

255 eal patients, and follow-up, including serum alpha-fetoprotein monitoring for early detection of mali

256 d time from primary resection to recurrence, alpha-fetoprotein more than 100 ng/mL at recurrence, rec

257 ellite nodules, albumin less than 3.5 gm/dL, alpha-fetoprotein more than 100 ng/mL, and any vascular

258 60 years, tumor size larger than 7.0 cm, and alpha-fetoprotein more than 100 ng/mL.

259 FGF19 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and

260 er RNA (mRNA) levels and reduced Albumin and Alpha-fetoprotein mRNA levels, indicating that they are

261 eatures were greatly elevated maternal serum alpha-fetoprotein (MSAFP) or amniotic fluid alpha-fetopr

262 Twenty-five patients had increased alpha fetoprotein (n = 18), human chorionic gonadotropin

263 ype (albumin-positive, transferrin-positive, alpha-fetoprotein-negative) and are able to proliferate

264 n of neuronal cellular adhesion molecule and alpha-fetoprotein, neuroectodermal, and endodermal marke

265 Only tumor variables of alpha-fetoprotein, number, total diameter, microvascular

266 inal nonseminoma (group A) and elevations of alpha-fetoprotein of 100 ng/mL or greater or of human ch

267 years), especially when combined with serum alpha fetoprotein or tumor staging.

268 essable patients with elevated CSF levels of alpha-fetoprotein or betahuman chorionic gonadotropin ha

269 ction of either one liver cancer marker, the alpha-fetoprotein, or the detection of Hepatitis C Virus

270 d with the standard HCC serum protein marker alpha fetoprotein (P = 0.57).

271 almitic acid, suggesting that the high serum alpha-fetoprotein phenotype of G1, associated with the k

272 Cytokeratin 19-, A6- and alpha-fetoprotein-positive cells within tumors were hepa

273 striking increase in the number of c-kit and alpha-fetoprotein-positive progenitors, without altering

274 and were predominantly H.4 antigen-positive, alpha-fetoprotein-positive, and OV6-negative.

275 Neonatal alpha-fetoprotein prevents circulating estrogens from ac

276 under age 40; p < 0.001), with greater serum alpha-Fetoprotein production (median level: HBV-1000 ng/

277 s simultaneously stimulated both albumin and alpha-fetoprotein promoters with minimal competition, bu

278 in activation early in liver development and alpha-fetoprotein reactivation during liver regeneration

279 The best alpha-fetoprotein reduction ranged from 32% to 95%.

280 t, by a locus that is unlinked to AFP called Alpha-fetoprotein regulator 1 (Afr1).

281 the level of Gpc3 induction is controlled by alpha-fetoprotein regulator 2 (Afr2).

282 f the albumin gene family that we have named Alpha-fetoprotein Related Gene (ARG) since it exhibits g

283 is B found no survival benefit with periodic alpha-fetoprotein screening.

284 accessing the brain, therefore, to overcome alpha-fetoprotein sequestration of E2, estrogen replacem

285 An alpha-fetoprotein serum level of 100 ng/mL identified by

286 Patients were subdivided according to alpha-fetoprotein serum levels (i.e., normal </= 20 ng/m

287 Alpha-fetoprotein serum levels have no prognostic meanin

288 ng persons with chronic HBV semiannually for alpha-fetoprotein since 1982.

289 m known genes present in fetal liver include alpha-fetoprotein, stem cell factor, erythroid alpha-spe

290 apid loss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver c

291 Of 11 patients with elevated alpha-fetoprotein, three (27%) had decreases of 50% or m

292 rimester quadruple screening (measurement of alpha-fetoprotein, total human chorionic gonadotropin, u

293 erm has recently been shown to interact with alpha-fetoprotein transcription factor and repress chole

294 cPR included a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval f

295 We measured serum alpha-fetoprotein, unconjugated estriol, human chorionic

296 ity of California at San Francisco criteria, alpha-fetoprotein, up-to-7 criteria, TTV, and platelet c

297 Increased serum alpha-fetoprotein was a negative prognostic variable.

298 An 8-mer peptide (EMTOVNOG) derived from alpha-fetoprotein was compared with tamoxifen for activi

299 Human alpha-fetoprotein was never expressed, but in some mice,

300 Combined expression of SCD and alpha-fetoprotein were associated with outcomes of patie